HOME >> MEDICINE >> NEWS
UK study suggests possible link between colorectal cancer and human growth hormone therapy

Authors of an observational study in this week's issue of THE LANCET highlight a possible link between human growth hormone therapy and an increased risk of colorectal cancer. The investigators comment that further evidence is required before firm conclusions can be made, and stress that there is no evidence from their study as to whether there is an association between modern synthetic growth hormone treatment and increased cancer risk.

Human pituitary growth hormone was widely used to counteract short stature in children and young adults up to the mid 1980s; since then synthetic growth hormone has replaced human growth hormone therapy. Previous research has suggested a possible link between naturally occurring growth hormone concentrations and an increased risk of cancer; however there are no long-term follow-up data on growth-hormone-treated patients to support this association.

Anthony Swerdlow, Michael Preece, and colleagues from The Institute of Cancer Research and Institute of Child Health, UK, did a population study to investigate cancer incidence and death in 1848 people in the UK who were treated during childhood and early adulthood with human pituitary growth hormone between 1959 and 1985. The risk of cancer in the study population was compared with that in the general population.

Patients treated with human pituitary growth hormone had an almost threefold increased risk of death from cancer overall, and were at around an eleven times greater risk of dying from colorectal cancer or Hodgkin's disease. After the exclusion of patients whose reason for growth hormone treatment rendered them at a high risk of cancer, the risk of incidence of colorectal cancer was significant, as were the risks of death from colorectal cancer or Hodgkin's disease.

Anthony Swerdlow comments: "Our data do not show conclusively whether cancer incidence is increased by growth hormone treatment, but they do suggest the need for increased awareness of
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
25-Jul-2002


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. UMaine study looks at infants and chronic nighttime crying
3. Chronic pain treatments more effective when taken together, new study shows
4. UNC study: Most N.C. family practitioners engage in unrecognized community service
5. New study in Nature demonstrates protection against cell death during heart attack
6. UCSF study offers insight into human circadian rhythms
7. International breast cancer prevention study launches in the United States and Canada
8. UW study shows blacks and Latinos are more satisfied with physicians of the same race
9. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study
10. Advertising by academic medical centers may risk eroding public trust, says study
11. Fat may promote inflammation, new study suggests

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology:
Cached News: